Literature DB >> 16258529

Kinetics of dendritic cell chimerism and T cell chimerism in allogeneic hematopoietic stem cell recipients.

S Boeck1, M Hamann, V Pihusch, T Heller, H Diem, B Rolf, R Pihusch, H-J Kolb, M Pihusch.   

Abstract

Dendritic cells (DC) as potent antigen-presenting cells (APC) and T cells as effector cells play an essential role in the pathophysiology of both graft-versus-host (GvH) and graft-versus-leukemia (GvL) reactions after transplantation. Therefore, we determined the kinetics of DC and T-cell chimerism establishment after allogeneic hematopoietic cell transplantation (AHCT) in a group of 144 patients, using fluorescence-activated cell sorting (FACS) or magnetic cell sorting (MACS) followed by FISH or STR-PCR analysis for chimerism evaluation. In all, three cell lines investigated (CD3(+) T cells, CD11c(+) DC1 and CD123(+) DC2), we found a rapid and consistent establishment of complete donor chimerism (CDC) in over 70% of all patients during the first 6 weeks after AHCT. The rate of patients with CDC increased significantly over time within the first year after transplantation. A related donor (P=0.004) as well as an underlying lymphatic leukemia (P=0.03) were found to be significantly associated with development of MC in T cells. No significant correlation between DC or T cell chimerism and GvHD or relapse was detected. Our results thus demonstrate a fast and stable CDC in DC1, DC2 and T cells after AHCT that continuously increases over time in nearly all patients.

Entities:  

Mesh:

Year:  2006        PMID: 16258529     DOI: 10.1038/sj.bmt.1705217

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin.

Authors:  Albert C Yeh; Paul V O'Donnell; Gary Schoch; Paul J Martin; Chris McFarland; Jeannine S McCune; Jason P Cooper; Kris Doney; Mary E D Flowers; Mohamed L Sorror; Frederick R Appelbaum; Barry E Storer; Ted Gooley; H Joachim Deeg
Journal:  Bone Marrow Transplant       Date:  2021-11-05       Impact factor: 5.174

2.  Direct and indirect antigen presentation lead to deletion of donor-specific T cells after in utero hematopoietic cell transplantation in mice.

Authors:  Amar Nijagal; Chris Derderian; Tom Le; Erin Jarvis; Linda Nguyen; Qizhi Tang; Tippi C Mackenzie
Journal:  Blood       Date:  2013-04-22       Impact factor: 22.113

3.  Prognostic utility of routine chimerism testing at 2 to 6 months after allogeneic hematopoietic cell transplantation.

Authors:  Ghada I Mossallam; Azza M Kamel; Barry Storer; Paul J Martin
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

Review 4.  The role of dendritic cells in graft-versus-tumor effect.

Authors:  Tomomi Toubai; Nathan Mathewson; Pavan Reddy
Journal:  Front Immunol       Date:  2014-02-21       Impact factor: 7.561

5.  Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission.

Authors:  Cornelis R van der Torren; Yvette van Hensbergen; Susanne Luther; Zohara Aghai; Zuzana Stachová Rychnavská; Manon Slot; Sicco Scherjon; Nicolaus Kröger; Arnold Ganser; Eva M Weissinger; Els Goulmy; Lothar Hambach
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

6.  Prolonged Survival of Subcutaneous Allogeneic Islet Graft by Donor Chimerism without Immunosuppressive Treatment.

Authors:  Brend Ray-Sea Hsu; Shin-Huei Fu; Aline Yen Ling Wang
Journal:  Int J Endocrinol       Date:  2017-06-21       Impact factor: 3.257

7.  Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-Cell Interaction.

Authors:  Peter van Balen; Boris van der Zouwen; Alwine B Kruisselbrink; Matthijs Eefting; Karoly Szuhai; Ekaterina S Jordanova; J H F Falkenburg; Inge Jedema
Journal:  Front Immunol       Date:  2018-02-27       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.